← Volver a las noticias

2 fuentesSeguimiento desde 17 sept, 12:52

<a href="https://www.fiercepharma.com/pharma/still-bull-novos-ceo-honoring-heritage-and-planning-future-amid-corporate-rebrand" hreflang="en">'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand</a>

CompartirX WhatsApp Facebook LinkedIn

Novo Nordisk

Cobertura cronológica

17 de septiembre
Más reciente17 sept, 12:52
<a href="https://www.fiercebiotech.com/pharma/still-bull-novos-ceo-honoring-heritage-and-planning-future-amid-corporate-rebrand" hreflang="en">'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand</a>
Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to chief rival Eli Lilly—isn’t one to make changes for the sake of change.
Fierce Biotech•Fraiser Kansteiner
Primera noticia17 sept, 12:52
<a href="https://www.fiercepharma.com/pharma/still-bull-novos-ceo-honoring-heritage-and-planning-future-amid-corporate-rebrand" hreflang="en">'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand</a>
Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to chief rival Eli Lilly—isn’t one to make changes for the sake of change.
Fierce Pharma•Fraiser Kansteiner